BIVI Company Profile and Key Details
BioVie Inc.
BIVI Stock Price Chart
Stock Price Today
BioVie Inc. (BIVI) stock declined over -8.48%, trading at $2.05 on NASDAQ, down from the previous close of $2.24. The stock opened at $2.23, fluctuating between $1.95 and $2.29 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Company Information
| Employees | 14 |
| Beta | 0.9 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
BioVie Inc. (NASDAQ: BIVI) stock price is $2.05 in the last trading session. During the trading session, BIVI stock reached the peak price of $2.29 while $1.95 was the lowest point it dropped to. The percentage change in BIVI stock occurred in the recent session was -8.48% while the dollar amount for the price change in BIVI stock was -$0.19.
The NASDAQ listed BIVI is part of Biotechnology industry that operates in the broader Healthcare sector. BioVie Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Cuong Viet Do M.B.A., MBA
Pres, Chief Executive Officer & Director
Dr. Joseph M. Palumbo M.D.
Chief Medical Officer
Ms. Joanne Wendy Kim CPA
Chief Financial Officer, Treasurer & Corporation Sec.
Dr. Penelope Markham Ph.D.
Executive Vice President of Liver Disease R&D
Ms. Denise Smith
Senior Vice President of Manufacturing & Devel.
Mr. Clarence N. Ahlem
Executive Vice President of Neuroscience Product Devel.
Ms. Sarah Overton Hoit
Chief Social Impact Officer
BIVI's closing price is 97.11% higher than its 52-week low of $1.04 where as its distance from 52-week high of $33.10 is -93.81%.
Number of BIVI employees currently stands at 14.
Official Website of BIVI is: https://bioviepharma.com
BIVI could be contacted at phone 775 888 3162 and can also be accessed through its website. BIVI operates from 680 West Nye Lane, Carson City, NV 89703, United States.
BIVI stock volume for the day was 1.48M shares. The average number of BIVI shares traded daily for last 3 months was 3.35M.
The market value of BIVI currently stands at $37.83M with its latest stock price at $2.05 and 18.45M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com